Vanguard Group Inc. Buys 72,817 Shares of Celldex Therapeutics, Inc. $CLDX

Vanguard Group Inc. lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 1.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,027,407 shares of the biopharmaceutical company’s stock after purchasing an additional 72,817 shares during the period. Vanguard Group Inc. owned 0.06% of Celldex Therapeutics worth $109,384,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Aster Capital Management DIFC Ltd bought a new stake in Celldex Therapeutics in the 3rd quarter valued at $26,000. Wilmington Savings Fund Society FSB bought a new stake in Celldex Therapeutics in the 3rd quarter valued at $42,000. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the period. Quantbot Technologies LP bought a new stake in Celldex Therapeutics in the 3rd quarter valued at $63,000. Finally, Strs Ohio bought a new stake in Celldex Therapeutics in the 3rd quarter valued at $75,000.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Stifel Nicolaus reiterated a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Barclays increased their price objective on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. The Goldman Sachs Group increased their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday, March 2nd. Finally, Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective on the stock in a research report on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $48.00.

Celldex Therapeutics Stock Performance

CLDX opened at $32.00 on Wednesday. The firm has a market cap of $2.51 billion, a P/E ratio of -7.51 and a beta of 0.98. Celldex Therapeutics, Inc. has a 52-week low of $18.47 and a 52-week high of $35.79. The business’s fifty day moving average is $31.82 and its 200-day moving average is $27.98.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.80 million. On average, research analysts predict that Celldex Therapeutics, Inc. will post -4.53 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.